Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18190230 | 0.89 | CHRM5 (0.43) | CHRM5CHKASLC6A2 | |
| SCHEMBL1268616 | 0.79 | TAAR1 (0.45) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8281666 | 0.77 | CHRM5 (0.52) | CHRM5CHKASLC6A2 | |
| SCHEMBL14409566 | 0.77 | CHRM5 (0.52) | CHRM5CHKAMAPTSMN1; SMN2F2 | |
| SCHEMBL22542431 | 0.76 | TMEM97 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6241015 | 0.76 | ALDH1A1 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL28320582 | 0.76 | PRMT1 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL5542550 | 0.76 | PRMT1 (0.48) | CHRM5PRMT1NOS1NOS2SMN1; SMN2 | |
| SCHEMBL25963028 | 0.75 | NOS1 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL5395464 | 0.75 | CHRM5 (0.50) | CHRM5CHKASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-5057528-A | AMINO-PYRIDINE COMPOUNDS USEFUL AS ANTI-ARRHYTHMIC AGENTS | PFIZER INC. (US) | 1991-10-15 | — | — | US | disclosed |
| US-4968704-A | PROLONG DURATION OF ACTION POTENTIAL IN CARDIAC MUSCLE AND CONDUCTING TISSUE | PFIZER INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0359389-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | ABL1, CRKL, MGMT | CHRM5 338/4885CHKA 201/4885ROCK1 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.